Abstract
We carried out a nested case–control study to measure the rate ratio (RR) for invasive female breast cancer in relation to non-steroidal anti-inflammatory drug (NSAID) use. The source population consisted of the female beneficiaries of the Saskatchewan Prescription Drug Plan from 1981 to 1995 with no history of cancer since 1970. Four controls/case, matched on age and sampling time, were randomly selected. Dispensing rates during successive time periods characterized NSAID exposure. RRs associated with exposure during each period were adjusted for exposure during the others. Confounding by other determinants was studied in analyses adjusted with data obtained by interviewing samples of subjects accrued from mid-1991 to mid-1995. We accrued 5882 cases and 23 517 controls. Increasing NSAID exposure 2–5 years preceding diagnosis was associated with a trend towards a decreasing RR (P -trend = 0.003); for the highest exposure level RR = 0.76, 95% confidence interval 0.63–0.92. This protective effect could not be attributed to confounding by other determinants. In analyses involving only the cases, NSAID exposure 2–5 and 6–10 years preceding diagnosis was associated with significantly reduced risks of presenting with a large tumour (> 5 cm diameter) or distant metastasis, but not regional lymph node metastasis. The use of NSAIDs may retard the growth of breast cancers and prevent distant metastasis. © 2000 Cancer Research Campaign
Keywords: breast neoplasms, anti-inflammatory agents, non-steroidal, epidemiology, case–, control studies
Full Text
The Full Text of this article is available as a PDF (91.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cain K. C., Breslow N. E. Logistic regression analysis and efficient design for two-stage studies. Am J Epidemiol. 1988 Dec;128(6):1198–1206. doi: 10.1093/oxfordjournals.aje.a115074. [DOI] [PubMed] [Google Scholar]
- Collet J. P., Sharpe C., Belzile E., Boivin J. F., Hanley J., Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer. 1999 Sep;81(1):62–68. doi: 10.1038/sj.bjc.6690651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Connolly J. M., Liu X. H., Rose D. P. Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor. Nutr Cancer. 1996;25(3):231–240. doi: 10.1080/01635589609514447. [DOI] [PubMed] [Google Scholar]
- Connolly J. M., Rose D. P. Effects of fatty acids on invasion through reconstituted basement membrane ('Matrigel') by a human breast cancer cell line. Cancer Lett. 1993 Dec 10;75(2):137–142. doi: 10.1016/0304-3835(93)90198-i. [DOI] [PubMed] [Google Scholar]
- Day N. E., Byar D. P., Green S. B. Overadjustment in case-control studies. Am J Epidemiol. 1980 Nov;112(5):696–706. doi: 10.1093/oxfordjournals.aje.a113042. [DOI] [PubMed] [Google Scholar]
- Egan K. M., Stampfer M. J., Giovannucci E., Rosner B. A., Colditz G. A. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 1996 Jul 17;88(14):988–993. doi: 10.1093/jnci/88.14.988. [DOI] [PubMed] [Google Scholar]
- Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat. 1995;36(2):109–118. doi: 10.1007/BF00666033. [DOI] [PubMed] [Google Scholar]
- Friedman G. D., Ury H. K. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst. 1980 Oct;65(4):723–733. doi: 10.1093/jnci/65.4.723. [DOI] [PubMed] [Google Scholar]
- Gammon M. D., John E. M., Britton J. A. Recreational and occupational physical activities and risk of breast cancer. J Natl Cancer Inst. 1998 Jan 21;90(2):100–117. doi: 10.1093/jnci/90.2.100. [DOI] [PubMed] [Google Scholar]
- Gridley G., McLaughlin J. K., Ekbom A., Klareskog L., Adami H. O., Hacker D. G., Hoover R., Fraumeni J. F., Jr Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993 Feb 17;85(4):307–311. doi: 10.1093/jnci/85.4.307. [DOI] [PubMed] [Google Scholar]
- Han E. K., Arber N., Yamamoto H., Lim J. T., Delohery T., Pamukcu R., Piazza G. A., Xing W. Q., Weinstein I. B. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat. 1998 Apr;48(3):195–203. doi: 10.1023/a:1005924730450. [DOI] [PubMed] [Google Scholar]
- Harris R. E., Namboodiri K. K., Farrar W. B. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996 Mar;7(2):203–205. doi: 10.1097/00001648-199603000-00017. [DOI] [PubMed] [Google Scholar]
- Harris R. E., Namboodiri K., Stellman S. D., Wynder E. L. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med. 1995 Mar;24(2):119–120. doi: 10.1006/pmed.1995.1022. [DOI] [PubMed] [Google Scholar]
- Hubbard N. E., Chapkin R. S., Erickson K. L. Inhibition of growth and linoleate-enhanced metastasis of a transplantable mouse mammary tumor by indomethacin. Cancer Lett. 1988 Dec 1;43(1-2):111–120. doi: 10.1016/0304-3835(88)90222-4. [DOI] [PubMed] [Google Scholar]
- Hudson N., Balsitis M., Everitt S., Hawkey C. J. Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs. Gut. 1995 Aug;37(2):191–194. doi: 10.1136/gut.37.2.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hunter C. P., Redmond C. K., Chen V. W., Austin D. F., Greenberg R. S., Correa P., Muss H. B., Forman M. R., Wesley M. N., Blacklow R. S. Breast cancer: factors associated with stage at diagnosis in black and white women. Black/White Cancer Survival Study Group. J Natl Cancer Inst. 1993 Jul 21;85(14):1129–1137. doi: 10.1093/jnci/85.14.1129. [DOI] [PubMed] [Google Scholar]
- Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998 Mar 18;90(6):455–460. doi: 10.1093/jnci/90.6.455. [DOI] [PubMed] [Google Scholar]
- Isomäki H. A., Hakulinen T., Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31(11):691–696. doi: 10.1016/0021-9681(78)90071-1. [DOI] [PubMed] [Google Scholar]
- Khoo N. K., Chan F. P., Saarloos M. N., Lala P. K. Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2. Clin Exp Metastasis. 1992 Jul;10(4):239–252. doi: 10.1007/BF00133559. [DOI] [PubMed] [Google Scholar]
- Lala P. K., Al-Mutter N., Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer. 1997 Nov 4;73(3):371–380. doi: 10.1002/(sici)1097-0215(19971104)73:3<371::aid-ijc12>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
- Mickey R. M., Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989 Jan;129(1):125–137. doi: 10.1093/oxfordjournals.aje.a115101. [DOI] [PubMed] [Google Scholar]
- Richardson J. L., Langholz B., Bernstein L., Burciaga C., Danley K., Ross R. K. Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and year. Br J Cancer. 1992 Jun;65(6):922–926. doi: 10.1038/bjc.1992.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Risch H. A., Howe G. R. Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study. Am J Epidemiol. 1994 Apr 1;139(7):670–683. doi: 10.1093/oxfordjournals.aje.a117057. [DOI] [PubMed] [Google Scholar]
- Robertson F. M., Parrett M. L., Joarder F. S., Ross M., Abou-Issa H. M., Alshafie G., Harris R. E. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett. 1998 Jan 9;122(1-2):165–175. doi: 10.1016/s0304-3835(97)00387-x. [DOI] [PubMed] [Google Scholar]
- Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994 Mar;5(2):138–146. doi: 10.1097/00001648-199403000-00003. [DOI] [PubMed] [Google Scholar]
- Taketo M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst. 1998 Oct 21;90(20):1529–1536. doi: 10.1093/jnci/90.20.1529. [DOI] [PubMed] [Google Scholar]
- Thompson H. J., Briggs S., Paranka N. S., Piazza G. A., Brendel K., Gross P. H., Sperl G. J., Pamukcu R., Ahnen D. J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst. 1995 Aug 16;87(16):1259–1260. [PubMed] [Google Scholar]
- Thun M. J., Namboodiri M. M., Calle E. E., Flanders W. D., Heath C. W., Jr Aspirin use and risk of fatal cancer. Cancer Res. 1993 Mar 15;53(6):1322–1327. [PubMed] [Google Scholar]
- Thune I., Brenn T., Lund E., Gaard M. Physical activity and the risk of breast cancer. N Engl J Med. 1997 May 1;336(18):1269–1275. doi: 10.1056/NEJM199705013361801. [DOI] [PubMed] [Google Scholar]
- Vainio H., Morgan G. Cyclo-oxygenase 2 and breast cancer prevention. Non-steroidal anti-inflammatory agents are worth testing in breast cancer. BMJ. 1998 Sep 26;317(7162):828–828. doi: 10.1136/bmj.317.7162.828. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Walter S. D., Day N. E. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol. 1983 Dec;118(6):865–886. doi: 10.1093/oxfordjournals.aje.a113705. [DOI] [PubMed] [Google Scholar]
- Ziche M., Jones J., Gullino P. M. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst. 1982 Aug;69(2):475–482. [PubMed] [Google Scholar]